Solid Biosciences (SLDB) Enterprise Value (2017 - 2026)

Solid Biosciences has disclosed Enterprise Value across 10 years of filings, most recently posting -$380.7 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$380.7 million, down 80.73% year-over-year; the trailing twelve-month figure through Mar 2026 was -$380.7 million (down 80.73% YoY), and the FY2025 annual result was -$187.8 million, down 134.12% from the prior year.
• Enterprise Value came in at -$380.7 million for Q1 2026 at Solid Biosciences, down from -$187.8 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$54.5 million in Q2 2022 to a low of -$380.7 million in Q1 2026.
• The 5-year median for Enterprise Value is -$185.5 million (2023), against an average of -$184.3 million.
• Across the five-year window, Enterprise Value jumped 72.82% in 2022 and tumbled 193.67% in 2023, its largest moves.
• Solid Biosciences' Enterprise Value stood at -$213.7 million in 2022, then soared by 42.15% to -$123.6 million in 2023, then soared by 35.11% to -$80.2 million in 2024, then sank by 134.12% to -$187.8 million in 2025, then tumbled by 102.65% to -$380.7 million in 2026.
• The last three Enterprise Value figures came in at -$380.7 million (Q1 2026), -$187.8 million (Q4 2025), and -$236.1 million (Q3 2025), per Business Quant data.